Natalizumab: A new treatment for relapsing remitting multiple sclerosis

Keyphrases

• Relapsing-remitting multiple Sclerosis 100%
• Natalizumab 100%
• Interferon-α (IFN-α) 42%
• Hazard Ratio 28%
• Confidence Interval 28%
• Monotherapy 28%
• Progressive multifocal Leukoencephalopathy 28%
• Disability Progression 28%
• Phase II Trial 28%
• Annualized Relapse Rate 28%
• Monoclonal Antibody 14%
• Placebo 14%
• Integrin 14%
• Loss of Effectiveness 14%
• Long-run Risk 14%
• T2-hyperintense Lesion 14%
• Rapidly Evolving 14%
• New Disease 14%
• High Disease Activity 14%
• Disease-modifying Therapy 14%

Neuroscience

• Natalizumab 100%
• Relapsing Remitting Multiple Sclerosis 100%
• Interferon 42%
• Progressive Multifocal Leukoencephalopathy 28%
• Placebo 14%
• Integrin 14%
• Monoclonal Antibody 14%